Anna A Ivanova

Dr. Anna A Ivanova

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2023 in eLife
Verified
Journal Article
Open access
MWMeghan E Wynne
Meghan E Wynne
OOOluwaseun Ogunbona
Oluwaseun Ogunbona
ALAlicia R Lane
Alicia R Lane
AGAvanti Gokhale
Avanti Gokhale
SZStephanie A Zlatic
Stephanie A Zlatic
VFVictor Faundez
Victor Faundez
Mitochondria influence cellular function through both cell-autonomous and non-cell autonomous mechanisms, such as production of paracrine and endocrine factors. Here, we demonstrate that mitochondrial regulation of the secretome is more extensive than previously appreciated, as both genetic and pharmacological disruption of the electron transport chain caused upregulation of the Alzheimer’s disease risk factor apolipoprotein E (APOE) and other secretome components. Indirect disruption of the electron transport chain by gene editing of SLC25A mitochondrial membrane transporters as well as direct genetic and pharmacological disruption of either complexes I, III, or the copper-containing complex IV of the electron transport chain elicited upregulation of APOE transcript, protein, and secretion, up to 49-fold. These APOE phenotypes were robustly expressed in diverse cell types and iPSC-derived human astrocytes as part of an inflammatory gene expression program. Moreover, age- and genotype-dependent decline in brain levels of respiratory complex I preceded an increase in APOE in the 5xFAD mouse model. We propose that mitochondria act as novel upstream regulators of APOE-dependent cellular processes in health and disease.

4 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SDSamuel Druzak
Samuel Druzak
EIElizabeth Iffrig
Elizabeth Iffrig
Blaine RobertsBlaine Roberts
Blaine Roberts
TZTiantian Zhang
Tiantian Zhang
KFKirby S. Fibben
Kirby S. Fibben
CMCheryl L. Maier
Cheryl L. Maier
The pathogenesis of multi-organ dysfunction associated with severe acute SARS-CoV-2 infection remains poorly understood. Endothelial damage and microvascular thrombosis have been identified as drivers of COVID-19 severity, yet the mechanisms underlying these processes remain elusive. Here we show alterations in fluid shear stress-responsive pathways in critically ill COVID-19 adults as compared to non-COVID critically ill adults using a multiomics approach. Mechanistic in-vitro studies, using microvasculature-on-chip devices, reveal that plasma from critically ill COVID-19 adults induces fibrinogen-dependent red blood cell aggregation that mechanically damages the microvascular glycocalyx. This mechanism appears unique to COVID-19, as plasma from non-COVID sepsis patients demonstrates greater red blood cell membrane stiffness but induces less significant alterations in overall blood rheology. Multiomics analyses in pediatric patients with acute COVID-19 or the post-infectious multi-inflammatory syndrome in children (MIS-C) demonstrate little overlap in plasma cytokine and metabolite changes compared to adult COVID-19 patients. Instead, pediatric acute COVID-19 and MIS-C patients show alterations strongly associated with cytokine upregulation. These findings link high fibrinogen and red blood cell aggregation with endotheliopathy in adult COVID-19 patients and highlight differences in the key mediators of pathogenesis between adult and pediatric populations.

19 October 2021 in Journal of Mass Spectrometry and Advances in the Clinical Lab
Verified
Journal Article
Open access
GRGregory B. Reis
Gregory B. Reis
JRJon C. Rees
Jon C. Rees
AIAnna A Ivanova
Anna A Ivanova
ZKZsuzsanna Kuklenyik
Zsuzsanna Kuklenyik
NDNathan M. Drew
Nathan M. Drew
JBJohn Barr
John Barr
• Lipid degradation was induced by storage at typical sample preparation temperatures. • Identification of low abundance lipids that increased several-fold during incubation. • Enzymatic hydrolysis and oxidation were identified as likely causes of degradation. • Most high abundance lipids that degrade do so within method variability.

31 October 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CCChih-Yu Chen
Chih-Yu Chen
KMKristal Maner-Smith
Kristal Maner-Smith
MKManoj Khadka
Manoj Khadka
JAJun Ahn
Jun Ahn
XGXueyun L. Gulbin
Xueyun L. Gulbin
EOEric A. Ortlund
Eric A. Ortlund
The biology of individual lipid species and their relevance in Alzheimer’s disease (AD) remains incompletely understood. To explore the lipidomic biomarkers associated with cognition function and neuropathological changes in AD, we utilize non-targeted mass spectrometry on 316 post-mortem brains from participants in the Religious Orders Study (ROS) or Rush Memory and Aging Project (MAP) cohorts classified as control, asymptomatic AD (AAD), or symptomatic AD (SAD), and integrate the lipidomics data with untargeted proteomics from the same individuals. We find that lysophosphatidylethanolamine (LPE) and lysophosphatidylcholine (LPC) species are significantly lower in SAD than controls or AAD. Lipid-protein network analyses reveal that LPE/LPC modules are significantly associated with protein modules involved in MAPK/metabolism, post-synaptic density, and cell-ECM interaction pathways, and correlate with better antemortem cognition and reduced AD neuropathology. Particularly, LPE 22:6 [sn-1] is significantly decreased SAD and exerts a pronounced influence on protein changes relevant to neurotransmitter-driven post synaptic changes and plasticity compared to other lysophospholipids species. These findings suggest LPE 22:6 as a potential lipid signature and therapeutic target for AD.

7 October 2009 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
YLYanmei Liu
Yanmei Liu
HMHassan Mziaut
Hassan Mziaut
AIAnna A Ivanova
Anna A Ivanova
MSMichele Solimena
Michele Solimena
Pancreatic β‐cells are the sole source of insulin, the major hormonal regulator of glycaemia. In physiological and pathological conditions with increased insulin demand, β‐cells adjust their insulin output either through increased insulin secretory granule (ISG) biogenesis and secretion, or hyperplasia. Failure of these compensatory mechanisms eventually results in hyperglycaemia and diabetes mellitus. Both of these major adaptive behaviours are positively regulated by several extrinsic factors, such as glucose, GLP‐1, insulin and growth hormones (GH). Still unclear, however, it is how β‐cells in response to these stimuli opt for one or the other strategy at a given time. Here we review recent advances concerning the factors and pathways that enhance ISG biogenesis and β‐cell replication, and propose the existence of ‘switch factors' that play a key role in regulating the shift between these two adaptive responses.

8 October 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
AIAnna A Ivanova
Anna A Ivanova
JRJon C. Rees
Jon C. Rees
BPBryan A. Parks
Bryan A. Parks
MAMichael Andrews
Michael Andrews
MGMichael Gardner
Michael Gardner
JBJohn Barr
John Barr
Aberrations in lipid and lipoprotein metabolic pathways can lead to numerous diseases, including cardiovascular disease, diabetes, neurological disorders, and cancer. The integration of quantitative lipid and lipoprotein profiling of human plasma may provide a powerful approach to inform early disease diagnosis and prevention. In this study, we leveraged data-driven quantitative targeted lipidomics and proteomics to identify specific molecular changes associated with different metabolic risk categories, including hyperlipidemic, hypercholesterolemic, hypertriglyceridemic, hyperglycemic, and normolipidemic conditions. Based on the quantitative characterization of serum samples from 146 individuals, we have determined individual lipid species and proteins that were significantly up- or down-regulated relative to the normolipidemic group. Then, we established protein–lipid topological networks for each metabolic category and linked dysregulated proteins and lipids with defined metabolic pathways. To evaluate the differentiating power of integrated lipidomics and proteomics data, we have built an artificial neural network model that simultaneously and accurately categorized the samples from each metabolic risk category based on the determined lipidomics and proteomics profiles. Together, our findings provide new insights into molecular changes associated with metabolic risk conditions, suggest new condition-specific associations between apolipoproteins and lipids, and may inform new biomarker discovery in lipid metabolism-associated disorders.